ArticleNature cancer2021
Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 95 citations in OpenAlex.
- Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.JCO precision oncology · 2025Trial
- Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.Investigational new drugs · 2024Trial
- Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.Investigational new drugs · 2024Trial
- PI(3,5)PScience advances · 2026Article
- Lysosomal metabolism in pancreatic cancer and its crosstalk with host physiology.Genes & development · 2026Review
- A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer.Cancer cell · 2026Article
- Targeting PIKfyve: Chemical Biology and Drug Discovery Insights.Chemical biology & drug design · 2026Review
- PI4K and PIPK families in breast cancer: subtype-specific oncogenic mechanisms and precision therapeutic strategies.Molecular biology reports · 2026Review
- A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Article
- PIP5K3 upregulation correlates with unfavorable prognosis in patients with nasopharyngeal carcinoma.Histology and histopathology · 2026Article
- Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors.Cell reports. Medicine · 2026Article
- PIKfyve is required for efficient phagosomal Rab7 acquisition and the delivery and fusion of early macropinosomes to phagosomes.Journal of cell science · 2026Article
- Targeting IPNature communications · 2026Article
- Article
- Crosstalk between NRP1 and autophagy in the tumor microenvironment: from molecular mechanisms to therapeutic targeting.Frontiers in immunology · 2026Review
- PIKfyve mediates the maturation of mycobacteria-containing vesicles.Frontiers in cellular and infection microbiology · 2026Article
- Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic.Frontiers in pharmacology · 2026Review
- Programmed Cell Death in Urological Cancers: Orchestrating the Immune Microenvironment and Immunotherapy.Oncology research · 2026Review
- In silico discovery and experimental validation of natural derivatives as inhibitor of phosphoinositide Kinase, PIKfyve.Journal of computer-aided molecular design · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 7 institutions in 4 countries.
Yuanyuan QiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Jae Eun ChoiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Jean C TienMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Stephanie A SimkoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Thekkelnaycke RajendiranDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Josh N VoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Andrew D DelektaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Lisha WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Lanbo XiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Nathan B HodgeMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Parth DesaiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Sergio MendozaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Kristin JucketteMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Alice XuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Tanu SoniMichigan Regional Comprehensive Metabolomics Resource Core, Ann Arbor, MI, USA.
Fengyun SuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Rui WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Jiali YuDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Ilona KryczekDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-3130-2533
Xiao-Ming WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Xiaoju WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Javed SiddiquiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Zhen WangSchool of Pharmacy, Jinan University, Guangzhou, China.
Amélie BernardCNRS, Laboratoire de Biogenèse Membranaire, Université de Bordeaux, Bordeaux, France.
Ester Fernandez-SalasMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Nora M NavoneDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephanie J EllisonMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Ke DingSchool of Pharmacy, Jinan University, Guangzhou, China.
Eeva-Liisa EskelinenInstitute of Biomedicine, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0003-0006-7785
Elisabeth I HeathKarmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.ORCID http://orcid.org/0000-0003-1381-2713
Daniel J KlionskyLife Sciences Institute, Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-7828-8118
Weiping ZouDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0001-7952-3549
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.ORCID http://orcid.org/0000-0001-9282-3415
University of Michigan · USHoward Hughes Medical Institute · USJinan University · CNCentre National de la Recherche Scientifique · FRThe University of Texas MD Anderson Cancer Center · USUniversity of Turku · FIWayne State University · US
Funding
VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCERP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 1995 to 2013
$31.3MTissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6MCELLULAR &MOLECULAR BASIS OF DISEASE TRAINING PROGRAMT32GM008061 · NIGMS · NORTHWESTERN UNIVERSITY · PI CARTHEW, RICHARD W. · 1985 to 2022
$17.1MThe mechanism and regulation of autophagyR35GM131919 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DANIEL J. KLIONSKY · 2019 to 2026
$6.4MExploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4MNaive T cells in Cancer Immune Evasion and ImmunotherapyR01CA217510 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2017 to 2021
$3.3MHoward Hughes Medical InstituteNCI NIH HHS P50 CA069568NCI NIH HHS P50 CA186786NCI NIH HHS R01 CA217510NCI NIH HHS R35 CA231996NIGMS NIH HHS R35 GM131919NIGMS NIH HHS T32 GM008061
Abstract
Multi-tyrosine kinase inhibitors (MTKIs) have thus far had limited success in the treatment of castration-resistant prostate cancer (CRPC). Here, we report a phase I-cleared orally bioavailable MTKI, ESK981, with a novel autophagy inhibitory property that decreased tumor growth in diverse preclinical models of CRPC. The anti-tumor activity of ESK981 was maximized in immunocompetent tumor environments where it upregulated
Indexed as
Immune Checkpoint InhibitorsProstatic Neoplasms, Castration-ResistantAutophagyHumansImmunotherapyMalePhosphatidylinositol 3-KinasesTumor MicroenvironmentImmune Checkpoint InhibitorsPhosphatidylinositol 3-KinasesPIKFYVE protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.